Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Daytrana

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

44 API Suppliers, 20 USDMF, 17 CEP/COS, 2 JDMF, 4 EU WC, 9 KDMF, 20 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

45 Drugs in Development

45 Drugs in Development

FINISHED DOSAGE FORMULATIONS

493 FDF Dossiers, 262 FDA Orange Book, 111 Europe, 53 Canada, 34 South Africa, 33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG, TABLET;ORAL - 20MG, TABLET;ORAL - 5MG, TABLET, EXTENDED RELEASE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 5MG/ML, CAPSULE, EXTENDED RELEASE;ORAL - 10MG, CAPSULE, EXTENDED RELEASE;ORAL - 15MG, CAPSULE, EXTENDED RELEASE;ORAL - 20MG, CAPSULE, EXTENDED RELEASE;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, CAPSULE, EXTENDED RELEASE;ORAL - 50MG, CAPSULE, EXTENDED RELEASE;ORAL - 60MG, TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 20MG, TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 30MG, TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 40MG, TABLET, EXTENDED RELEASE;ORAL - 18MG, TABLET, EXTENDED RELEASE;ORAL - 27MG, TABLET, EXTENDED RELEASE;ORAL - 36MG, TABLET, EXTENDED RELEASE;ORAL - 54MG, CAPSULE, EXTENDED RELEASE;ORAL - 10MG, CAPSULE, EXTENDED RELEASE;ORAL - 20MG, CAPSULE, EXTENDED RELEASE;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, CAPSULE, EXTENDED RELEASE;ORAL - 50MG, CAPSULE, EXTENDED RELEASE;ORAL - 60MG, SOLUTION;ORAL - 10MG/5ML, SOLUTION;ORAL - 5MG/5ML, TABLET, CHEWABLE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, CHEWABLE;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, CHEWABLE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 6 Evonik, 8 Rochem International Inc, 20 SPI Pharma, 21 DKSH, 2 Pharm-RX Chemical, 1 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 8 Kirsch Pharma, 4 ACG Worldwide, 12 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 38 BASF, 1 Bioplus Life Sciences, 3 CD Formulation, 20 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 2 Finar, 11 Gangwal Chemicals, 2 Hayashibara, 13 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 3 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 20 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 9 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 36 Roquette, 9 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 6 The Dow Chemical Company, 2 Valens Pharmachem, 3 Vasa Pharmachem, 3 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

93 Fillers, Diluents & Binders, 81 Coating Systems & Additives, 56 Thickeners and Stabilizers, 49 Controlled & Modified Release, 40 Direct Compression, 39 Taste Masking, 35 Granulation, 34 Solubilizers, 30 Film Formers & Plasticizers, 30 Topical, 29 Parenteral, 27 Disintegrants & Superdisintegrants, 26 Lubricants & Glidants, 24 Chewable & Orodispersible Aids, 12 Co-Processed Excipients, 11 Emulsifying Agents, 11 Rheology Modifiers, 9 Empty Capsules, 7 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 70 News #PharmaBuzz

GLOBAL SALES INFORMATION

47 US Medicaid Prescriptions, 89 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

10 APIs, 2 FDF Dossiers

PATENTS & EXCLUSIVITIES

224 US Patents, 57 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Veranova	U.S.A	Myungin Pharmaceutical Co., Ltd.	20251117-209-J-2059	methylphenidate hydrochloride	2025-11-17	Macfarlan Smith Limited	United Kingdom	10, Wheatfield Road, Edinburgh EH11 2QA, United Kingdom
29/11/2025	SCI Pharmtech	Taiwan	Aging Life Science Co., Ltd.	20180907-209-J-55	methylphenidate hydrochloride	2018-09-07	SCI Pharmtech, Inc	Taiwan	No.61, Ln.309, Haihu N. Rd., Luzhu Dist. Taoyuan City 33856, Taiwan

Daytrana

Daytrana

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

44 API Suppliers

20 USDMF

17 CEP/COS

2 JDMF

4 EU WC

9 KDMF

20 NDC API

15 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

45 Drugs in Development

FINISHED DOSAGE FORMULATIONS

493 FDF Dossiers

262 FDA Orange Book

111 Europe

53 Canada

34 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG

TABLET;ORAL - 20MG

TABLET;ORAL - 5MG

TABLET, EXTENDED RELEASE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FOR SUSPENSION, EXTENDED RELEASE;ORAL - 5MG/ML

CAPSULE, EXTENDED RELEASE;ORAL - 10MG

CAPSULE, EXTENDED RELEASE;ORAL - 15MG

CAPSULE, EXTENDED RELEASE;ORAL - 20MG

CAPSULE, EXTENDED RELEASE;ORAL - 30MG

CAPSULE, EXTENDED RELEASE;ORAL - 40MG

CAPSULE, EXTENDED RELEASE;ORAL - 50MG

CAPSULE, EXTENDED RELEASE;ORAL - 60MG

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 20MG

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 30MG

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL - 40MG

TABLET, EXTENDED RELEASE;ORAL - 18MG

TABLET, EXTENDED RELEASE;ORAL - 27MG

TABLET, EXTENDED RELEASE;ORAL - 36MG

TABLET, EXTENDED RELEASE;ORAL - 54MG

CAPSULE, EXTENDED RELEASE;ORAL - 10MG

CAPSULE, EXTENDED RELEASE;ORAL - 20MG

CAPSULE, EXTENDED RELEASE;ORAL - 30MG

CAPSULE, EXTENDED RELEASE;ORAL - 40MG

CAPSULE, EXTENDED RELEASE;ORAL - 50MG

CAPSULE, EXTENDED RELEASE;ORAL - 60MG

SOLUTION;ORAL - 10MG/5ML

SOLUTION;ORAL - 5MG/5ML

TABLET, CHEWABLE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, CHEWABLE;ORAL - 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, CHEWABLE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

6 Evonik

8 Rochem International Inc

20 SPI Pharma

21 DKSH

2 Pharm-RX Chemical

1 Boai NKY Pharmaceuticals Ltd

8 Gangwal Healthcare

10 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

2 Pfanstiehl

8 Kirsch Pharma

4 ACG Worldwide

12 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

38 BASF

1 Bioplus Life Sciences

3 CD Formulation

20 Corel Pharma Chem

TABLET, EXTENDED RELEASE;ORAL - 20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, CHEWABLE;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, CHEWABLE;ORAL - 2.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, CHEWABLE;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons